• Perospirone Inhibits Vascular Kv1.5 Channels

  2026-09-18

  A 2025 Journal of Applied Toxicology study identifies a previously unrecognized electrophysiological action of Perospirone in freshly isolated rabbit coronary arterial smooth muscle cells. The drug inhibited vascular voltage-gated K+ currents in a concentration-dependent, use-independent manner, with pharmacological evidence implicating Kv1.5 channels and raising questions about cardiovascular effects beyond its established antipsychotic mechanism.

• Anlotinib hydrochloride: Angiogenesis Workflows

  2026-09-17

  Build mechanism-led angiogenesis experiments around Anlotinib hydrochloride, from receptor phosphorylation to endothelial migration and tube formation. This practical guide combines dose selection, pathway validation, comparative controls, and troubleshooting for reproducible cancer research.

• Masitinib (AB1010) Workflow Guide

  2026-09-17

  Masitinib (AB1010), SKU A2942, provides a DMSO-compatible research tool for focused KIT, PDGFRα, and PDGFRβ inhibition in cellular, biochemical, mast-cell, and cancer models. It is not appropriate for aqueous or ethanol-based workflows, broad-spectrum kinase profiling, or clinical dosing decisions without separate validation.

• 10 mM dNTP Mixture: From PCR Input to Assay Control

  2026-09-16

  The 10 mM dNTP mixture is more than a convenient PCR reagent: its defined composition can function as a control point in DNA synthesis and nucleic-acid assay design. This article connects nucleotide standardization with intracellular trafficking research while clearly separating supported evidence from practical workflow recommendations.

• CP-673451: Biomarker-Aware PDGFR Research

  2026-09-16

  CP-673451 is a selective PDGFRα/β inhibitor for dissecting receptor signaling, angiogenesis, and tumor biology. This guide develops a biomarker-aware assay strategy that connects PDGFR pharmacology with ATRX-deficient glioma research without overstating translational evidence.

• CLCC1 and Herpesvirus Nuclear Egress Fusion

  2026-09-15

  A 2024 bioRxiv preprint identifies the host factor CLCC1 as essential for the membrane-fusion step of herpes simplex virus 1 nuclear egress. The study separates viral NEC-driven budding from host-dependent fusion and connects herpesvirus capsid export with nuclear pore complex membrane insertion, providing a framework for investigating host-controlled stages of infection.

• Thiamet G Workflow for O-GlcNAc Studies

  2026-09-15

  Thiamet G provides a controlled way to elevate protein O-GlcNAcylation in cell, disease, and mechanistic assays. This workflow connects tauopathy research and leukemia studies with a carefully bounded extension into trophoblast ferroptosis and preeclampsia research.

• EZ Cap™ OVA mRNA: Designing Interpretable Immune Assays

  2026-09-14

  Learn how EZ Cap™ OVA mRNA can function as a standardized antigen-expression input for separating delivery performance, protein expression enhancement, and inflammatory biology. This article connects assay design to recent low-inflammation mRNA delivery research while emphasizing practical controls and interpretation.

• Inducing Right Ventricular-Like Cardiomyocytes from hPSCs

  2026-09-14

  Saito et al. developed a differentiation strategy that shifts human pluripotent stem cell cardiac progenitors toward an anterior second heart field-like state and produces right ventricular-like cardiomyocytes. The resulting cells differed from left ventricular-like controls in gene expression, spontaneous contraction, calcium handling, and cell size, providing a useful framework for chamber-specific disease modeling.

• BEND Lipids Improve mRNA Delivery and Gene Editing

  2026-09-13

  The reference study introduces branched endosomal disruptor lipids that improve lipid nanoparticle delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes. By linking terminal branching to enhanced endosomal penetration, the work provides a rational design strategy for hepatic gene editing and T-cell engineering.

• LY2109761: TGF-β Signaling Research Workflows

  2026-09-12

  LY2109761 enables controlled interrogation of TGF-β-driven phosphorylation, cell-cycle arrest, tumor behavior, and fibrotic responses. This workflow-focused guide connects receptor inhibition with Smad2/3, CDC25A, radiosensitivity, and assay troubleshooting for reproducible preclinical research.

• ATRX Loss Sensitizes Glioma Cells to PDGFR Inhibitors

  2026-09-11

  Pladevall-Morera and colleagues identified a genotype-associated drug vulnerability in high-grade glioma: ATRX-deficient cells were more sensitive to several receptor tyrosine kinase and PDGFR inhibitors than ATRX-intact counterparts. The study also found enhanced toxicity when selected RTK inhibitors were combined with temozolomide, supporting ATRX status as a factor for interpreting targeted-therapy studies.

• PAD4-IN-2 TFA: An Assay-Design Guide

  2026-09-11

  PAD4-IN-2 TFA, also known as Compound 5i TFA, is a tumor-targeted PAD4 inhibitor for studying H3 citrullination, NET biology, metastasis, and immune remodeling. This guide focuses on experimental decision-making: how to distinguish direct tumor-cell effects from neutrophil-mediated mechanisms and select interpretable assays.

• BV6: From IAP Biology to Translational Design

  2026-09-10

  BV6 is more than a compound for apoptosis assays: it is a mechanistic probe for testing how IAP-dependent survival shapes treatment response. This thought-leadership analysis connects BV6-mediated IAP antagonism with apoptosis induction, radiosensitization, chemotherapy response, and disease-model design while using recent ovarian cancer muscle research to clarify what pathway modulation can—and cannot—establish. The result is a practical framework for translational researchers building evidence beyond conventional product-page claims.

• Anlotinib Hydrochloride in Angiogenesis Assays

  2026-09-10

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor suited to mechanism-led angiogenesis workflows, combining receptor-level validation with migration and tube-formation readouts. This guide translates its VEGFR2, PDGFRβ, and FGFR1 activity into practical assay design, comparative studies, and troubleshooting strategies for cancer research.

8459 records 1/564 page Next 12345 下5页 Last page